公开(公告)号：BRPI0617180A2

公开(公告)日：2013-02-26

申请号：BRPI0617180

申请日：2006-10-05

Applicant: BASF SE

Inventor： KOLTER KARL ,  QUADIR ANISUL ,  MEYER-BOEHM KATHRIN

IPC: A61K9/16 ,  A61K9/20 ,  C07C57/30

Abstract: A directly tabletable ibuprofen formulation comprising a) 50-99% by weight of crystalline ibuprofen, b) 1-15% by weight of a finely divided excipient with a surface area of at least 100 m2/g, and c) 0-40% by weight of further excipients, with the proviso that the total amount of components a) to c) corresponds to 100% by weight, where at least 50% of the surface of the ibuprofen crystals are covered with the finely divided excipient.

公开(公告)号：MX2010006005A

公开(公告)日：2010-06-15

申请号：MX2010006005

申请日：2008-12-10

Applicant: BASF SE

Inventor： KOLTER KARL ,  ANGEL MAXIMILIAN ,  MEYER-BOEHM KATHRIN

IPC: A61K9/20

Abstract: Sales poliméricas solubles en agua de medicamentos que son raramente solubles en agua, que consisten de un polímero con carácter de anión que es soluble en agua a valores de pH de 2-13 y un medicamento raramente soluble con carácter de catión.

公开(公告)号：AT459375T

公开(公告)日：2010-03-15

申请号：AT06830232

申请日：2006-11-30

Applicant: BASF SE

Inventor： BOUILLO NATHALIE ,  KHVOROST ALEXANDER ,  MUENSTER INGO ,  DOBRAWA RAINER ,  MEYER-BOEHM KATHRIN ,  LANGE RONALD FRANS MARIA

IPC: A61K47/32 ,  C08F8/00

Abstract: Vinyllactam copolymers modified with polyalkylene oxide side-chains, and use thereof as solubilizers for substances which are sparingly soluble in water, and preparations comprising such copolymers.

公开(公告)号：CA2707282A1

公开(公告)日：2009-06-18

申请号：CA2707282

申请日：2008-12-10

Applicant: BASF SE

Inventor： KOLTER KARL ,  ANGEL MAXIMILIAN ,  MEYER-BOEHM KATHRIN

IPC: A61K9/20

Abstract: The invention relates to polymeric, water-soluble salts of poorly water-soluble medicaments, comprising a polymer which is water-soluble at pH 2-13 of anionic character with a poorly-soluble medicament of cationic character.

公开(公告)号：MX387178B

公开(公告)日：2025-03-18

申请号：MX2019000846

申请日：2019-01-18

Applicant: BASF SE

Inventor： WIGBERS CHRISTOF WILHELM ,  WAGNER DANIEL ,  KOLTER KARL ,  MEYER-BOEHM KATHRIN ,  SCHORDING PETER ,  SINGH RAAJVINDER ,  BRUHNS STEFAN ,  HELGASON THRANDUR ,  DOBLER WALTER ,  PELLETIER WOLF

IPC: A23L33/15 ,  A23K20/174 ,  A23L33/155 ,  A23P10/20 ,  A61K8/31 ,  A61K8/35 ,  A61K8/37 ,  A61K8/67 ,  A61K9/14 ,  A61K31/015 ,  A61K31/05 ,  A61K31/07 ,  A61K31/12 ,  A61K31/122 ,  A61K31/235 ,  A61K31/355 ,  A61K31/375 ,  A61K31/59 ,  A61K45/06 ,  A61K47/14 ,  A61P3/02 ,  A61Q19/00 ,  C07C403/24

Abstract: La presente invención se refiere a una formulación pulverulenta de vitamina donde la vitamina esencialmente tiene un tamaño de partícula menor que 0.7 µm y que comprende una cantidad eficaz de galato de propilo, y también a procesos para producir esta formulación, y a formulaciones que pueden obtenerse mediante estos procesos y a la utilización de estas como alimento para animales, alimentos, suplementos alimenticios, productos para el cuidado personal o composiciones farmacéuticas. Las formulaciones de la invención tienen una estabilidad mejorada en comparación con la técnica anterior.

公开(公告)号：AU2017300595A1

公开(公告)日：2019-02-28

申请号：AU2017300595

申请日：2017-07-17

Applicant: BASF SE

Inventor： MEYER-BOEHM KATHRIN ,  HELGASON THRANDUR ,  SINGH RAAJVINDER ,  DOBLER WALTER ,  SCHORDING PETER ,  WIGBERS CHRISTOF WILHELM ,  KOLTER KARL ,  BRUHNS STEFAN ,  PELLETIER WOLF ,  WAGNER DANIEL

IPC: A23L33/15 ,  A23K20/174 ,  A23L33/155 ,  A23P10/20 ,  A61K8/31 ,  A61K31/07 ,  C07C403/24

Abstract: The present invention relates to a powdery vitamin preparation, in which the vitamin has substantially a particle size of less than 0.7 µm and which contains an effective amount of propyl gallate. The invention also relates to methods for the production of said preparation, to preparations that can be obtained according to said methods and to their use as animal feed, food, food supplements, body care products or pharmaceutical agents. The preparations according to the invention have a stability that is improved compared to the prior art.

公开(公告)号：BRPI0812064A2

公开(公告)日：2014-11-25

申请号：BRPI0812064

申请日：2008-06-03

Applicant: BASF SE

Inventor： KOLTER KARL ,  SCHOENHERR MICHAEL ,  GEBERT SILKE ,  MEYER-BOEHM KATHRIN ,  MASCHKE ANGELIKA

IPC: A61K9/00 ,  A61K9/16 ,  A61K9/20

Abstract: Pharmaceutical formulation in the form of agglomerates comprising A) an excipient content composed of a) 60-97% by weight of sugar or sugar alcohols, b) 1-25% by weight of a disintegrant, c) 1-15% by weight of water-insoluble, film-forming polymers d) 0-15% by weight of water-soluble polymers and e) 0-15% by weight of further pharmaceutically customary excipients the total of the components a) to e) being 100% by weight, and B) at least one active ingredient.

公开(公告)号：BRPI0615581A2

公开(公告)日：2012-12-11

申请号：BRPI0615581

申请日：2006-08-31

Applicant: BASF SE

Inventor： KOLTER KARL ,  ANGEL MAXIMILIAN ,  MITTTWOLLEN JAN-PETER ,  MEYER-BOEHM KATHRIN ,  SCHILLO SIMONE

IPC: A61K9/48

Abstract: A process for producing gelatin-free soft capsule shells based on polyvinyl alcohol-polyether graft copolymers as shell polymers, which comprises heating an aqueous solution comprising at least 45% by weight, based on the total weight of the solution, of a polymer component, where the polymer component consists of a polyvinyl alcohol-polyether graft copolymer or a mixture of polyvinyl alcohol-polyether graft copolymers and polyvinyl alcohol, extruding the solution at a temperature of at least 70° C., and solidifying the resulting film by cooling.

公开(公告)号：CA2688389A1

公开(公告)日：2008-12-11

申请号：CA2688389

申请日：2008-06-02

Applicant: BASF SE

Inventor： KOLTER KARL ,  SCHOENHERR MICHAEL ,  GEBERT SILKE ,  MEYER-BOEHM KATHRIN ,  MASCHKE ANGELIKA

IPC: A61K9/00 ,  A61K9/16 ,  A61K9/20

Abstract: The invention relates to a pharmaceutical formulation in the form of compacts containing a) 60 - 97 % by weight of sugar or sugar alcohols, b) 1 - 25 % by weight of a disintegration agent selected from the group consisting of croscarmellose, sodium carboxymethyl starch and L-hydroxypropyl cellulose, c) 1 - 15 % by weight of water insoluble film-forming polymers, d) 0 - 15 % by weight of water-soluble polymers, and e) 0 - 15 % by weight of additional conventional pharmaceutical adjuvants, the sum of the components a) to e) totalling 100 % by weight.